VIRIOS THERAPEUTICS, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.2386 USD | -4.25% |
|
-4.18% | -58.50% |
| 20/06 | Maxim Initiates Virios Therapeutics at Buy Rating With $1 Price Target | MT |
| 20/05 | Top Midday Decliners | MT |
Valuation
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Capitalization 1 | 58.82 | 42.61 | 4.326 | 11.07 | 6.623 | - | - |
| Enterprise Value (EV) 1 | 58.82 | 42.61 | 4.326 | 11.07 | 6.623 | 6.623 | 6.623 |
| P/E ratio | -3.58 x | -2.66 x | -0.21 x | -2.05 x | -0.94 x | -1.28 x | -0.85 x |
| Yield | - | - | - | - | - | - | - |
| Capitalization / Revenue | - | - | - | - | - | - | - |
| EV / Revenue | - | - | - | - | - | - | - |
| EV / EBITDA | - | - | - | - | - | - | - |
| EV / FCF | - | - | - | - | -1.12 x | -0.77 x | -0.4 x |
| FCF Yield | - | - | - | - | -89.6% | -130% | -248% |
| Price to Book | - | - | - | - | - | - | - |
| Nbr of stocks (in thousands) | 7,832 | 8,330 | 18,330 | 19,258 | 27,758 | - | - |
| Reference price 2 | 7.510 | 5.115 | 0.2360 | 0.5750 | 0.2386 | 0.2386 | 0.2386 |
| Announcement Date | 18/03/21 | 17/03/22 | 14/03/23 | 29/02/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Net sales 1 | - | - | - | - | - | - | - |
| EBITDA | - | - | - | - | - | - | - |
| EBIT 1 | - | -15.64 | -12.32 | -5.447 | -5.756 | -6.996 | -11.24 |
| Operating Margin | - | - | - | - | - | - | - |
| Earnings before Tax (EBT) 1 | - | -15.96 | -12.25 | -5.296 | -5.606 | -6.154 | -8.605 |
| Net income 1 | -10.35 | -15.96 | -12.25 | -5.296 | -5.715 | -6.963 | -11.21 |
| Net margin | - | - | - | - | - | - | - |
| EPS 2 | -2.100 | -1.920 | -1.110 | -0.2800 | -0.2533 | -0.1867 | -0.2800 |
| Free Cash Flow 1 | - | - | - | - | -5.931 | -8.581 | -16.42 |
| FCF margin | - | - | - | - | - | - | - |
| FCF Conversion (EBITDA) | - | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - | - | - |
| Announcement Date | 18/03/21 | 17/03/22 | 14/03/23 | 29/02/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 | 2025 Q1 | 2025 Q2 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| EBIT 1 | -4.188 | -3.961 | -3.672 | -2.592 | -2.09 | -1.557 | -1.477 | -1.274 | -1.138 | - | -1.359 | -1.455 | -1.51 | - | - |
| Operating Margin | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Earnings before Tax (EBT) 1 | -4.511 | -3.96 | -3.667 | -2.576 | -2.045 | -1.517 | -1.441 | -1.235 | -1.103 | - | -1.314 | -1.47 | -1.527 | - | - |
| Net income 1 | -4.511 | -3.96 | -3.667 | -2.576 | -2.045 | -1.517 | -1.441 | -1.235 | -1.103 | - | -1.326 | -1.455 | -1.51 | - | - |
| Net margin | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| EPS 2 | -0.5400 | -0.4800 | -0.4400 | -0.2800 | -0.1100 | -0.0800 | -0.0800 | -0.0600 | -0.0600 | -0.0700 | -0.0633 | -0.0600 | -0.0633 | -0.0500 | -0.0500 |
| Dividend per Share | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Announcement Date | 17/03/22 | 12/05/22 | 11/08/22 | 14/11/22 | 14/03/23 | 12/05/23 | 10/08/23 | 13/11/23 | 29/02/24 | 09/05/24 | - | - | - | - | - |
1USD in Million2USD
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Net Debt | - | - | - | - | - | - | - |
| Net Cash position | - | - | - | - | - | - | - |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - | - |
| Free Cash Flow 1 | - | - | - | - | -5.93 | -8.58 | -16.4 |
| ROE (net income / shareholders' equity) | - | - | - | - | - | - | - |
| ROA (Net income/ Total Assets) | - | - | - | - | - | - | - |
| Assets 1 | - | - | - | - | - | - | - |
| Book Value Per Share | - | - | - | - | - | - | - |
| Cash Flow per Share | - | - | - | - | - | - | - |
| Capex | - | - | - | - | - | - | - |
| Capex / Sales | - | - | - | - | - | - | - |
| Announcement Date | 18/03/21 | 17/03/22 | 14/03/23 | 29/02/24 | - | - | - |
1USD in Million
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
2
Last Close Price
0.2386
USD
Average target price
1.8
USD
Spread / Average Target
+654.40%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -58.50% | 6.62M | |
| +16.49% | 122B | |
| +21.73% | 115B | |
| +22.53% | 26.64B | |
| -21.81% | 19.91B | |
| -16.73% | 16.32B | |
| -18.81% | 15.49B | |
| -44.74% | 15.52B | |
| +62.72% | 14.83B | |
| +3.09% | 13.67B |
- Stock Market
- Equities
- VIRI Stock
- Financials Virios Therapeutics, Inc.
